By Shannon Ellis, Staff Writer
©2015. REPRINTED WITH PERMISSION FROM THOMSON REUTERS.
SHANGHAI – Beijing-based Canbridge Life Sciences Inc. is a
biotech that seeks to bring Western innovation to Chinese patients
who have few if any treatment options. That licensing strategy has
led it to sign a deal with Apogenix GmbH, of Heidelberg, Germany,
for lead candidate APG101, an onco-immunotherapy targeting the
CD95 ligand for a highly lethal and diffi cult to treat type of brain
cancer, glioblastoma multiforme.
This allows to use the see for info sildenafil pfizer drug during different types of the inflammatory diseases. Until the climax, purchase cheap cialis drscoinc.com Penegra can boost the sex drive in men. An overall screening is a must if you repeatedly fail to achieve and sustain an erection. pharmacy levitra Most consumers are confused regarding the utility value of great store purchase levitra online Canadian drugs. A classic licensing deal structure, Canbridge has provided an
up-front payment, with the promise of milestones and royalties,
in exchange for the technology and rights to develop and
commercialize APG101 in China, Hong Kong and Macau. Canbridge
signed on for indications beyond glioblastoma as well.
“We are always actively looking for clinical-stage assets from
biotechs that hold promise for any unmet medical needs,
particularly in the oncology area,” said James Xue, chairman and
CEO of Canbridge. “Apogenix’s lead product, APG101, fi ts like a
glove.”